DWA
MLTX icon

Delos Wealth Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Delos Wealth Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6K Sell
1,000
-5,000
-83% -$82.8K 0.01% 160
2025
Q4 		$79.1K Buy
6,000
+4,000
+200% +$47.2K 0.05% 77
2025
Q3 		$14.3K Buy
+2,000
New +$104K 0.01% 165

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Delos Wealth Advisors's MLTX Position: Q1 2026 in Review

Delos Wealth Advisors reduced its MoonLake Immunotherapeutics (MLTX) stake by 83% in Q1 2026, selling an estimated $82.8K and leaving 1,000 shares worth $18.6K. The position accounts for 0.01% of the portfolio, ranked #160.

Delos Wealth Advisors first reported a position in MLTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $79.1K in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Delos Wealth Advisors held 1,000 shares of MoonLake Immunotherapeutics worth $18.6K as of Q1 2026.
  • Delos Wealth Advisors sold 5,000 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $82.8K.
  • MoonLake Immunotherapeutics made up 0.01% of Delos Wealth Advisors's portfolio in Q1 2026, its #160 holding.
  • Delos Wealth Advisors first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • Delos Wealth Advisors's MoonLake Immunotherapeutics position peaked at $79.1K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Delos Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.